5.2 U.S. and International Regulatory Frameworks

Certified Clinical Research Coordinator CCRC

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Scientific Concepts and Research Design

1.1 Protocol Elements 1.2 Study Design and Objectives 1.3 Study Endpoints and Biostatistics

2 Chapter 2: Ethical Principles and Guidelines

2.1 Ethical Principles (Declaration of Helsinki, Belmont Report) 2.2 Informed Consent Process and Documentation 2.3 Vulnerable Populations and Assent

3 Chapter 3: IRB/IEC Oversight and Participant Safety

3.1 IRB/IEC Functions and Oversight 3.2 Adverse Event Classification and Reporting 3.3 Safety Monitoring and Safety Reporting

4 Chapter 4: Participant Rights and Ethics

4.1 Participant Rights and Confidentiality (HIPAA/GDPR) 4.2 Conflicts of Interest 4.3 Ethical Scenarios in Clinical Trials

5 Chapter 5: Product Development and Regulatory Framework

5.1 Drug and Device Development Phases 5.2 U.S. and International Regulatory Frameworks 5.3 Investigational Product Investigator's Brochure (IB)

6 Chapter 6: Investigational Product Accountability

6.1 Investigational Product Labeling and Storage 6.2 Investigational Product Receipt, Dispensing, and Accountability 6.3 Investigational Product Return and Destruction

7 Chapter 7: Regulatory Submissions and Actions

7.1 Regulatory Submissions (IND, NDA, IDE, PMA) 7.2 Regulatory Actions and Compliance 7.3 Pharmacokinetics and Pharmacodynamics in Product Development

8 Chapter 8: Clinical Trial Operations and GCP Principles

8.1 Introduction to ICH E6 GCP Principles (including R3 updates) 8.2 Investigator Responsibilities under GCP 8.3 Sponsor Responsibilities and Oversight

9 Chapter 9: Essential Documents and Site Qualification

9.1 Essential Documents (Pre-study, During, Post-study) 9.2 Site Selection and Qualification 9.3 Quality Management and Standard Operating Procedures (SOPs)

10 Chapter 10: Protocol Deviations and Amendments

10.1 Protocol Adherence and Compliance 10.2 Protocol Deviations and Violations 10.3 Protocol Amendments and Version Control

11 Chapter 11: Monitoring Visits and Audits

11.1 Monitoring Preparation and Visit Types 11.2 Monitoring Visits (SIV, IMV, COV) 11.3 Regulatory Inspections and Site Audits

12 Chapter 12: Study and Site Management - Startup

12.1 Site Startup Operations 12.2 Site Budget and Contract Management 12.3 Site Staffing, Training, and Documentation

13 Chapter 13: Enrollment and Recruitment

13.1 Enrollment Management and Strategies 13.2 Participant Recruitment and Retention 13.3 Participant Compensation and Ethics

14 Chapter 14: Daily Trial Coordination

14.1 Visit Scheduling and Logistics 14.2 Equipment Maintenance and Calibration 14.3 Specimen Handling and Shipping (IATA/dangerous goods)

15 Chapter 15: Quality Improvement and Site Closeout

15.1 Participant Safety Management 15.2 Quality Improvement and Site Audits Preparation 15.3 Study and Site Closeout Procedures

16 Chapter 16: Source Documentation and Case Report Forms

16.1 Source Documentation Standards (ALCOA-C) 16.2 Case Report Forms and eCRF Completion 16.3 Electronic Data Capture (EDC) Systems

17 Chapter 17: Data Management and Queries

17.1 Data Management Processes 17.2 Data Queries and Discrepancy Resolution 17.3 Data Correction and Audit Trails

18 Chapter 18: Data Privacy and Records Retention

18.1 Data Privacy and Confidentiality 18.2 Records Retention and Archiving 18.3 Compliance in Clinical Trial Informatics

5.2 U.S. and International Regulatory Frameworks

Key Takeaways Explain This Topic AI

The FDA regulates medical products in the U.S. through centers like CDER for drugs, CBER for biologics, and CDRH for devices.

The International Council for Harmonisation (ICH), specifically the GCP E6 guideline, provides a unified standard for clinical trials across major global regions, facilitating mutual acceptance of clinical data.

The Declaration of Helsinki and the Belmont Report are foundational ethical documents that heavily influence modern international and U.S. regulatory frameworks.

Last updated: October 2026

Clinical research is a global enterprise. While a trial may be executed locally, the data is often submitted to multiple regulatory agencies worldwide. Therefore, CRCs must understand both the specific U.S. regulatory framework and the international guidelines that allow clinical data to cross borders.

U.S. Regulatory Framework: The FDA

In the United States, the Food and Drug Administration (FDA) is the primary regulatory authority responsible for ensuring the safety, efficacy, and security of human drugs, biological products, and medical devices.

The FDA organizes its regulatory oversight into specific centers:

CDER (Center for Drug Evaluation and Research): Regulates over-the-counter and prescription drugs, including biological therapeutics and generic drugs. CDER reviews Investigational New Drug (IND) applications and New Drug Applications (NDA).

CBER (Center for Biologics Evaluation and Research): Regulates biological and related products including blood, vaccines, allergenics, tissues, and cellular and gene therapies. CBER reviews Biologics License Applications (BLA).

CDRH (Center for Devices and Radiological Health): Responsible for the premarket approval of all medical devices, as well as overseeing the manufacturing, performance, and safety of these devices. CDRH reviews 510(k) notifications, Premarket Approvals (PMA), and Investigational Device Exemptions (IDE).

Key U.S. Regulations (Title 21 of the CFR)

For a CRC, the Code of Federal Regulations (CFR) Title 21 contains the binding laws for conducting clinical research. Key parts include:

21 CFR Part 11: Electronic Records and Electronic Signatures.

21 CFR Part 50: Protection of Human Subjects (Informed Consent).

21 CFR Part 54: Financial Disclosure by Clinical Investigators.

21 CFR Part 56: Institutional Review Boards.

21 CFR Part 312: Investigational New Drug Application.

21 CFR Part 812: Investigational Device Exemptions.

International Frameworks: EMA and PMDA

Outside the U.S., major markets have their own regulatory bodies with similar, yet distinct, procedures.

European Medicines Agency (EMA)

The EMA is responsible for the scientific evaluation, supervision, and safety monitoring of medicines in the European Union (EU).

A unique aspect of the EMA is the Centralised Procedure . This allows pharmaceutical companies to submit a single marketing-authorization application to the EMA. If approved, the product is authorized for marketing in all EU and European Economic Area (EEA) countries simultaneously, drastically streamlining the process compared to seeking individual approvals in each member state.

Pharmaceuticals and Medical Devices Agency (PMDA)

The PMDA is the Japanese regulatory agency. They conduct scientific reviews of marketing authorization applications of pharmaceuticals and medical devices, monitoring their post-market safety.

The Need for Harmonization: ICH

Historically, the FDA, EMA, and PMDA had entirely different requirements for clinical trial data and reporting. A sponsor had to conduct separate, duplicate trials for each region, dramatically increasing the time and cost of drug development.

To solve this, the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) was formed. The ICH brings together regulatory authorities and pharmaceutical industry representatives to discuss scientific and technical aspects of drug registration.

ICH Good Clinical Practice (GCP) E6

For a CRC, the most important ICH guideline is ICH E6(R3) , which replaced E6(R2) across ACRP exams from July 15, 2026. This document provides a unified standard for Good Clinical Practice.

Its stated objective is to provide a unified standard to facilitate the mutual acceptance of clinical trial data for ICH member countries and regions by applicable regulatory authorities.

If a trial is conducted according to ICH GCP, the FDA will generally accept the data even if the trial was conducted entirely outside the U.S.

ICH E6 delineates the specific responsibilities of the Institutional Review Board/Independent Ethics Committee (IRB/IEC), the Investigator, and the Sponsor. It emphasizes that the rights, safety, and well-being of the trial participants are the most important considerations and should prevail over interests of science and society.

Foundational Ethical Documents

The modern regulatory frameworks did not emerge from a vacuum; they were built upon foundational ethical documents created in response to historical abuses.

The Nuremberg Code (1947): Established following the Nuremberg trials, it introduced the absolute requirement for voluntary consent and stated that the benefits of research must outweigh the risks.

The Declaration of Helsinki (1964, updated continuously): Developed by the World Medical Association (WMA), this is a statement of ethical principles for medical research involving human subjects. It introduced the concept of an independent committee to review research protocols (the precursor to the IRB) and established guidelines for using placebo controls. ICH GCP explicitly states that clinical trials should be conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki.

The Belmont Report (1979): Issued in the U.S. following the public outcry over the Tuskegee Syphilis Study. It identifies three core ethical principles:

Respect for Persons: Acknowledges autonomy and mandates informed consent.

Beneficence: The obligation to do no harm, maximize possible benefits, and minimize possible harms.

Justice: Fairness in the distribution of the burdens and benefits of research (e.g., vulnerable populations should not be targeted simply because they are easily accessible).

Understanding these regulations and ethical foundations is not just about passing an exam; it provides the "why" behind the intense documentation and rigorous procedural adherence required in daily CRC duties.